Acta Pharmacologica Sinica 2007 March; 28 (3): 404-409; doi: 10.1111/j.1745-7254.2007.00510.x

Aim: To assess the anti-hepatitis B virus (HBV) effect of hyperoside extracted from Abelmoschus manihot (L) medik.

Methods: The human hepatoma Hep G2.2.15 cell culture system and duck hepatitis B virus (DHBV) infection model were used as in vivo and in vitro models to evaluate the anti-HBV effects.

Results: In the cell model, the 50% toxic concentration of hyperoside was 0.115 g/L; the maximum nontoxic concentration was 0.05 g/L. On the maximum nontoxic concentrations, the inhibition rates of hyperoside on HBeAg and HBsAg in the 2.2.15 cells were 86.41% and 82.27% on d 8, respectively. In the DHBV infection model, the DHBV­DNA levels decreased significantly in the treatment of 0.05 g· kg^-1·d^-1 and 0.10 g·kg^-1·d^-1 dosage groups of hyperoside (P<0.01). The inhibition of the peak of viremia was at the maximum at the dose of 0.10 g·kg^-1·d^-1 and reached 60.79% on d 10 and 69.78% on d 13, respectively.

Conclusion: These results suggested that hyperoside is a strong inhibitor of HBsAg and HBeAg secretion in 2.2.15 cells and DHBV­DNA levels in the HBV-infected duck model.

Keywords: hyperoside; hepatitis B virus; duck hepatitis B virus; antiviral agents